<DOC>
	<DOCNO>NCT00003732</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining one drug may kill cancer cell . PURPOSE : Phase I/II trial study effectiveness topotecan combine carboplatin paclitaxel treat patient stage II , stage III , stage IV ovarian cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Stage II , Stage III , Stage IV Ovarian Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose , dose-limiting toxicity , quantitative qualitative toxic effect oral topotecan combine intravenous carboplatin paclitaxel patient stage IIB , IIC , III , IV ovarian epithelial cancer . ( phase I close accrual 12/21/00 ) - Evaluate anti-tumor activity regimen patient population . OUTLINE : This multicenter , dose-escalation study topotecan . Patients receive oral topotecan day 1-5 paclitaxel IV 3 hour follow carboplatin IV 30 minute day 5 . Courses repeat every 21 day maximum 6 course absence disease progression unacceptable toxicity . - Phase I : Cohorts 3-6 patient receive escalate dos topotecan maximum tolerate dose ( MTD ) determine . The MTD define dose 2 6 patient experience dose-limiting toxicity . ( phase I close accrual 12/21/00 ) - Phase II : An additional 50 patient receive 6 course treatment phase I MTD . Patients follow every 3 month 2 year every 6 month 3 year . PROJECTED ACCRUAL : A total 80 patient ( 30 phase I 50 phase II ) accrue study . ( phase I close accrual 12/21/00 )</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm stage IIB , IIC , III , IV ovarian epithelial cancer Measurable evaluable lesion microscopic residual disease first surgery ( phase II patient ) No brain and/or leptomeningeal metastasis CT scan MRI unless asymptomatic without corticosteroid therapy PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 3 month Hematopoietic : Hemoglobin least 9.0 g/dL WBC least 3,500/mm3 Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) unless liver metastasis present Alkaline phosphatase great 2 time ULN* SGOT great 2 time ULN* NOTE : *No great 5 time ULN liver metastases present Renal : Creatinine great 1.5 time ULN Creatinine clearance least 60 mL/min Cardiovascular : No symptomatic cardiac disease , include clinical congestive heart failure arrhythmia require treatment No myocardial infarction within past 3 month Other : No malignancy except basal squamous cell skin cancer carcinoma situ cervix No uncontrolled infection No complete bowel obstruction condition would affect GI absorption motility No concurrent medical condition treatment platinum , taxane , camptothecin analogue contraindicate No concurrent medical condition would preclude study No mental disease No history allergy platinum taxanes , include drug contain cremophor ( e.g. , cyclosporine vitamin K ) Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent immunotherapy Chemotherapy : No prior camptothecin analogue No prior chemotherapy ovarian cancer No concurrent chemotherapy Endocrine therapy : See Disease Characteristics No concurrent hormonal therapy estrogen replacement Radiotherapy : No concurrent radiotherapy Surgery : See Disease Characteristics Other : At least 30 day 5 halflives since prior investigational therapy No concurrent investigational therapy No concurrent metoclopramide cisapride</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2002</verification_date>
	<keyword>stage IIB ovarian epithelial cancer</keyword>
	<keyword>stage IIC ovarian epithelial cancer</keyword>
	<keyword>stage IIIA ovarian epithelial cancer</keyword>
	<keyword>stage IIIB ovarian epithelial cancer</keyword>
	<keyword>stage IIIC ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
</DOC>